{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:01:12Z","timestamp":1791126072927,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.coviro.2011.10.019","type":"journal-article","created":{"date-parts":[[2011,11,14]],"date-time":"2011-11-14T00:26:31Z","timestamp":1321230391000},"page":"607-616","source":"Crossref","is-referenced-by-count":52,"title":["Anti-HCV drugs in the pipeline"],"prefix":"10.1016","volume":"1","author":[{"given":"Priscilla L","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie A","family":"Villareal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2011.10.019_bib0445","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/13305","article-title":"Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site","volume":"6","author":"Lesburg","year":"1999","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0450","doi-asserted-by":"crossref","first-page":"13034","DOI":"10.1073\/pnas.96.23.13034","article-title":"Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"96","author":"Bressanelli","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2011.10.019_bib0005_1","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1086\/656774","article-title":"RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients","volume":"202","author":"Le Pogam","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2011.10.019_bib0010","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/AAC.00294-11","article-title":"Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication","volume":"55","author":"Delang","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0015_1","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1128\/AAC.01317-07","article-title":"The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors","volume":"52","author":"McCown","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0020","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1128\/JVI.01980-09","article-title":"1a\/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus","volume":"84","author":"Nyanguile","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0025","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00307-11","article-title":"Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase","volume":"55","author":"Shih","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jviromet.2011.03.031","article-title":"Colony-forming assays reveal enhanced suppression of hepatitis C virus replication using combinations of direct-acting antivirals","volume":"174","author":"Graham","year":"2011","journal-title":"J Virol Methods"},{"key":"10.1016\/j.coviro.2011.10.019_bib0035_1","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2011.10.019_bib0040_1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/135965350901400505","article-title":"Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1\u20135","volume":"14","author":"Legrand-Abravanel","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coviro.2011.10.019_bib0045_1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jac\/dkn085","article-title":"Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients","volume":"61","author":"Le Pogam","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0050","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/13543784.2010.500285","article-title":"New NS5B polymerase inhibitors for hepatitis C","volume":"19","author":"Legrand-Abravanel","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.coviro.2011.10.019_bib0055","first-page":"862A","article-title":"Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy","volume":"46","author":"Reddy","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2011.10.019_bib0060","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/AAC.00400-06","article-title":"Mechanism of activation of beta-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase","volume":"51","author":"Murakami","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0065","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1016\/S0168-8278(11)61361-5","article-title":"First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon\/ribavirin in treatment-naive HCV G1\/4 patients: interim analysis for the JUMP-C trial","volume":"54","author":"Pockros","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0070","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0168-8278(10)60039-6","article-title":"Sustained virology response (SVR) following RG7128 1500mg BID\/PEG-IFN\/RBV for 28 days in HCV genotype 2\/3 prior non-responders","volume":"42","author":"Gane","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0075_1","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2011.10.019_bib0080","doi-asserted-by":"crossref","first-page":"49164","DOI":"10.1074\/jbc.M305041200","article-title":"Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro","volume":"278","author":"Migliaccio","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2011.10.019_bib0085","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1128\/AAC.49.5.2059-2069.2005","article-title":"Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay","volume":"49","author":"Ludmerer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0090_1","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1128\/AAC.00032-11","article-title":"Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of beta-D-2\u2032-deoxy-2\u2032-alpha-fluoro-2\u2032-beta-C-methylguanosine","volume":"55","author":"Lam","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0095","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1099\/vir.0.80204-0","article-title":"Hepatitis C virus NS5A: tales of a promiscuous protein","volume":"85","author":"Macdonald","year":"2004","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0100","series-title":"The 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy","article-title":"Discovery of potent NS5A inhibitors with favorable pharmacokinetics and robust activity in an HCV animal model","author":"Buckman","year":"2010"},{"key":"10.1016\/j.coviro.2011.10.019_bib0105","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/S0168-8278(11)60766-6","article-title":"In vitro profiling of GSK2336805, a potent and selective inhibitor of HCV NS5A","volume":"54","author":"Bechtel","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0110","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1016\/S0168-8278(11)61206-3","article-title":"Pharmacokinetics, safety and tolerability of the HCV NS5A inhibitor ABT-267 following single and multiple doses in healthy adult volunteers","volume":"54","author":"Dumas","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0115","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1128\/JVI.00215-11","article-title":"Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action","volume":"85","author":"Targett-Adams","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0120","unstructured":"Bruce J, Milbank J, Pryde DC, Tran TD: Hepatitis C Virus Inhibitors. US Patent 2011, WO\/2011\/004276."},{"key":"10.1016\/j.coviro.2011.10.019_bib0125","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/S0168-8278(11)60817-9","article-title":"Idenix NS5A HCV replication inhibitors with low picomolar, pan-genotypic in vitro antiviral activity","volume":"54","author":"Dousson","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0130","doi-asserted-by":"crossref","first-page":"S479","DOI":"10.1016\/S0168-8278(11)61214-2","article-title":"ACH-2928: a novel highly potent HCV NS5A inhibitor with favorable preclinical characteristics","volume":"54","author":"Huang","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0135","doi-asserted-by":"crossref","first-page":"S479","DOI":"10.1016\/S0168-8278(11)61215-4","article-title":"A potent highly HCV NS5A inhibitor EDP-239 with favorable preclinical pharmacokinetics","volume":"54","author":"Jiang","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0140_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2011.10.019_bib0145","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1016\/S0168-8278(11)61221-X","article-title":"Three-day, dose-ranging study of the HCV NS5A inhibitor GS-5885","volume":"54","author":"Lawitz","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0150","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0168-8278(10)60035-9","article-title":"Identification and characterization of PPI-461, a potent and selective HCV NS5A inhibitor with activity against all HCV genotypes","volume":"52","author":"Colonno","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0155","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/S0168-8278(10)61194-4","article-title":"Antiviral activity, pharmacokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients","volume":"52","author":"Gane","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0160","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1128\/AAC.00146-11","article-title":"Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures","volume":"55","author":"Lemm","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0165","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1128\/JVI.00253-11","article-title":"Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052","volume":"85","author":"Fridell","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0170","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nature03580","article-title":"Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase","volume":"435","author":"Tellinghuisen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2011.10.019_bib0175","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1128\/JVI.02352-08","article-title":"Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus","volume":"83","author":"Love","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0180_1","first-page":"S544","article-title":"First report of SVR12 for a NS5A replication complex inhibitor BMS-790052 in combination with PEG-IFN alpha-2A and RBV: phase 2A trial in treatment-naive HCV-genotype 1 subjects","volume":"52","author":"Pol","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0185","doi-asserted-by":"crossref","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2011.10.019_bib0190_1","doi-asserted-by":"crossref","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: in vitro and in vivo correlations","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2011.10.019_bib0195_1","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0200","doi-asserted-by":"crossref","first-page":"e1000546","DOI":"10.1371\/journal.ppat.1000546","article-title":"Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics","volume":"5","author":"Kaul","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2011.10.019_bib0205","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1128\/JVI.02614-07","article-title":"Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro","volume":"82","author":"Yang","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0210","doi-asserted-by":"crossref","first-page":"16998","DOI":"10.1074\/jbc.M109.007625","article-title":"The isomerase active site of cyclophilin A is critical for hepatitis C virus replication","volume":"284","author":"Chatterji","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2011.10.019_bib0215","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/hep.23281","article-title":"Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A","volume":"50","author":"Ciesek","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2011.10.019_bib0220","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.virol.2009.10.043","article-title":"Multiple cyclophilins involved in different cellular pathways mediate HCV replication","volume":"397","author":"Gaither","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2011.10.019_bib0225","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1074\/jbc.M809244200","article-title":"Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis\/trans isomerase activity of cyclophilins A and B","volume":"284","author":"Hanoulle","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2011.10.019_bib0230","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1099\/vir.0.018531-0","article-title":"Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes","volume":"91","author":"Chatterji","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0235","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molcel.2005.05.014","article-title":"Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase","volume":"19","author":"Watashi","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.coviro.2011.10.019_bib0240","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/hep.21809","article-title":"Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B","volume":"46","author":"Fernandes","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2011.10.019_bib0245","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.bcp.2008.12.019","article-title":"Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase","volume":"77","author":"Heck","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0250","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1128\/JVI.02550-08","article-title":"Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex","volume":"83","author":"Liu","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0255","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/j.1349-7006.2009.01263.x","article-title":"Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor","volume":"100","author":"Goto","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.coviro.2011.10.019_bib0260","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1128\/JVI.02524-06","article-title":"Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro","volume":"81","author":"Robida","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0265","doi-asserted-by":"crossref","first-page":"e1001118","DOI":"10.1371\/journal.ppat.1001118","article-title":"A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach","volume":"6","author":"Yang","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2011.10.019_bib0270","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1371\/journal.pone.0013687","article-title":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A","volume":"5","author":"Coelmont","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2011.10.019_bib0275","doi-asserted-by":"crossref","first-page":"20441","DOI":"10.1074\/jbc.M110.182436","article-title":"Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A","volume":"286","author":"Verdegem","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2011.10.019_bib0280","doi-asserted-by":"crossref","first-page":"7460","DOI":"10.1128\/JVI.00393-11","article-title":"Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner","volume":"85","author":"Foster","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0285","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1128\/AAC.00310-06","article-title":"NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon","volume":"50","author":"Ma","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0290_1","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22835","article-title":"The cyclophilin inhibitor Debio 025 combined with PEG IFN\u03b12a significantly reduces viral load in treatment-na\u00efve hepatitis C patients","volume":"49","author":"Flisiak","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2011.10.019_bib0295","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0168-8278(09)60091-X","article-title":"Safety, plasma pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection","volume":"50","author":"Hopkins","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0300_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.antiviral.2011.01.003","article-title":"Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy","volume":"89","author":"Lawitz","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2011.10.019_bib0305","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.21102","article-title":"The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro","volume":"43","author":"Paeshuyse","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2011.10.019_bib0310_1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.22131","article-title":"The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus","volume":"47","author":"Flisiak","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2011.10.019_bib0315_1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0168-8278(11)60006-8","article-title":"Once-daily alisporivir (DEB025) plus PEG-IFN-\u03b1-2A\/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment na\u00efve patients","volume":"54","author":"Flisiak","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0320","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/AAC.00660-09","article-title":"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro","volume":"54","author":"Hopkins","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0325_1","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1128\/AAC.00498-08","article-title":"Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance","volume":"52","author":"Mathy","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0330_1","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1128\/AAC.01236-09","article-title":"Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors","volume":"54","author":"Puyang","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0335","series-title":"6th International Workshop on Hepatitis C, Resistance and New Compounds","article-title":"Host targeting cyclophilin inhibitor alisporivir presents a high barrier to resistance with no cross-resistance to direct acting antivirals","author":"Tiongyip","year":"2011"},{"key":"10.1016\/j.coviro.2011.10.019_bib0340_1","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/AAC.00939-08","article-title":"Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors","volume":"53","author":"Coelmont","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0345","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1128\/JVI.76.12.5974-5984.2002","article-title":"Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex","volume":"76","author":"Egger","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0350","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.chom.2009.02.001","article-title":"A functional genomic screen identifies cellular cofactors of hepatitis C virus replication","volume":"5","author":"Tai","year":"2009","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2011.10.019_bib0355","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1073\/pnas.0902693106","article-title":"Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication","volume":"106","author":"Berger","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2011.10.019_bib0360","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1096\/fj.09-131920","article-title":"Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening","volume":"23","author":"Trotard","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.coviro.2011.10.019_bib0365","doi-asserted-by":"crossref","first-page":"16410","DOI":"10.1073\/pnas.0907439106","article-title":"A genome-wide genetic screen for host factors required for hepatitis C virus propagation","volume":"106","author":"Li","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2011.10.019_bib0370","doi-asserted-by":"crossref","first-page":"10058","DOI":"10.1128\/JVI.02418-08","article-title":"Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication","volume":"83","author":"Borawski","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0375","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.virol.2009.02.039","article-title":"Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication","volume":"387","author":"Vaillancourt","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2011.10.019_bib0380_1","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/nbt.1490","article-title":"Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis","volume":"26","author":"Einav","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0385_1","series-title":"18th International Symposium on HCV and Related Viruses","article-title":"The efficacy of an NS4B inhibitor in HCV infected PXB-mice","author":"Hamatake","year":"2011"},{"key":"10.1016\/j.coviro.2011.10.019_bib0390_1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.coviro.2011.10.019_bib0395","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.chom.2008.05.013","article-title":"Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome","volume":"4","author":"Jopling","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2011.10.019_bib0400","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1128\/JVI.00417-10","article-title":"Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122","volume":"84","author":"Jangra","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0405_1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1178178","article-title":"Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection","volume":"327","author":"Lanford","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.coviro.2011.10.019_bib0410_1","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/nm.2238","article-title":"Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1","volume":"16","author":"Herker","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2011.10.019_bib0415_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1128\/AAC.01081-08","article-title":"Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034)","volume":"53","author":"Flint","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.019_bib0420","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/S0168-8278(11)60427-3","article-title":"Four-week treatment with GS-9256 and tegobuvir (GS-9190), \u00b1 RBV \u00b1 PEG, results in enhanced viral suppression on follow-up PEG\/RBV therapy in genotype 1a\/1b HCV patients","volume":"54","author":"Foster","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0425","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1016\/S0168-8278(11)61365-2","article-title":"VX-222 with TVR alone or in combination with PEGinterferon alfa-2A and ribavirin in treatment-naive patients with chronic hepatitis C: Zenith study interim results","volume":"54","author":"Di Bisceglie","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0430","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, M\u00fcllhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, et al.: Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin, in patients with chronic hepatitis C: the SOUND-C1 trial. In 61th Annual Meeting of the American Association for the Study of Liver Diseases: Boston, MA; 2010.","DOI":"10.1053\/j.gastro.2011.08.051"},{"key":"10.1016\/j.coviro.2011.10.019_bib0435","doi-asserted-by":"crossref","first-page":"S543","DOI":"10.1016\/S0168-8278(11)61372-X","article-title":"Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCVRNA <LOD at day 14: first purine\/pyrimidine clinical combination data (the nuclear study)","volume":"54","author":"Lawitz","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2011.10.019_bib0440_1","doi-asserted-by":"crossref","first-page":"S536","DOI":"10.1016\/S0168-8278(11)61358-5","article-title":"Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN\/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders","volume":"54","author":"Lok","year":"2011","journal-title":"J Hepatol"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625711001386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625711001386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T03:08:47Z","timestamp":1686452927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625711001386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1879625711001386"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2011.10.019","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}